Endurant Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Endurant Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,563	Closed	-$3.11M	–	60
2021 Q2	$3.11M	Buy	+5,563	New	+$2.82M	0.85%	40
2020 Q1	–	Sell	-27,390	Closed	-$10.3M	–	64
2019 Q4	$10.3M	Buy	+27,390	New	+$9.22M	3.24%	10
2018 Q3	–	Sell	-5,300	Closed	-$1.83M	–	82
2018 Q2	$1.83M	Buy	5,300 +3,100	+141%	+$970K	0.79%	33
2018 Q1	$758K	Sell	2,200 -3,400	-61%	-$1.18M	0.28%	58
2017 Q4	$2.1M	Buy	+5,600	New	+$2.27M	0.64%	47
2017 Q2	–	Sell	-1,300	Closed	-$504K	–	99
2017 Q1	$504K	Sell	1,300 -900	-41%	-$334K	0.16%	77
2016 Q4	$808K	Buy	+2,200	New	+$837K	0.33%	57
2016 Q1	–	Sell	-746	Closed	-$405K	–	90
2015 Q4	$405K	Sell	746 -1,654	-69%	-$896K	0.14%	73
2015 Q3	$1.12M	Buy	+2,400	New	+$1.29M	0.37%	58

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Endurant Capital Management's REGN Position: Q3 2021 in Review

Endurant Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2021, closing a stake of 5,563 shares — an estimated $3.11M sold.

Endurant Capital Management first reported a position in REGN in Q3 2015 and held it in 9 quarters. The position peaked at $10.3M in Q4 2019. 1,018 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

Endurant Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Endurant Capital Management sold 5,563 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $3.11M.
Endurant Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2015 and held it in 9 quarters.
Endurant Capital Management's Regeneron Pharmaceuticals position peaked at $10.3M in Q4 2019.
1,018 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on Endurant Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.